GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

TWI · Jun 30, 2025

TITAN INTERNATIONAL INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000899751-25-000070General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

127.61% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensity20thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.19% · OPTIONAL · VALID

Operating cash generation20thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

3.11% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-13.41% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure90thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

103.67% · OPTIONAL · VALID

Gross margin30thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.gross_margin

15.03% · CORE · VALID

Operating margin20thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.operating_margin

2.20% · CORE · VALID

R&D intensity100thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

0.94% · OPTIONAL · VALID

SBC intensity60thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

0.30% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History15 statesHistory building
Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/9 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/9 normalizedLevel 3Sep 30, 20240/9 normalizedLevel 3Dec 31, 20247/9 normalizedLevel 3Mar 31, 20257/9 normalizedLevel 3Jun 30, 20257/9 normalizedLevel 3Sep 30, 20257/9 normalizedLevel 3Dec 31, 20259/9 normalizedLevel 3Mar 31, 20269/9 normalizedLevel 3Jun 30, 20269/9 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
119.83%
Current
127.61%
Delta
7.78%
Capex Intensity Decreased
Previous
3.06%
Current
2.19%
Delta
-0.87%
Cash Generation Increased
Previous
-7.86%
Current
3.11%
Delta
10.97%
Growth Decreased
Previous
1.76%
Current
-13.41%
Delta
-15.17%
Inventory Pressure Increased
Previous
92.92%
Current
103.67%
Delta
10.75%
Margin Increased
Previous
13.99%
Current
15.03%
Delta
1.04%
Profitability Decreased
Previous
2.40%
Current
2.20%
Delta
-0.20%
R And D Intensity Increased
Previous
0.93%
Current
0.94%
Delta
0.02%
Sbc Intensity Increased
Previous
-0.19%
Current
0.30%
Delta
0.49%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · TWI Fundamental State →Has State · TITAN INTERNATIONAL INC →Transitioned To · TWI Fundamental State →Transitioned To · TWI BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · TWI CAPEX_INTENSITY_DECREASED →Transitioned To · TWI CASH_GENERATION_INCREASED →Transitioned To · TWI GROWTH_DECREASED →Transitioned To · TWI INVENTORY_PRESSURE_INCREASED →Transitioned To · TWI MARGIN_INCREASED →Transitioned To · TWI PROFITABILITY_DECREASED →Transitioned To · TWI R_AND_D_INTENSITY_INCREASED →Transitioned To · TWI SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.